Short answer
IRONWOOD PHARMACEUTICALS INC (IRWD) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $107M (up 158.9% year over year) with net income of $41M.
Q1 2026 key financials · XBRL
- Revenue
- $107M
- +158.9% YoY
- Net income
- $41M
- +209.1% YoY
- Operating margin
- 68.1%
- EPS (diluted)
- $0.24
- +204.3% YoY
Source: XBRL data from the IRONWOOD PHARMACEUTICALS INC (IRWD) Q1 2026 10-Q on SEC EDGAR. USD.
IRONWOOD PHARMACEUTICALS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $106.5M, up $65.4M YoY, driven by higher U.S. LINZESS net-profit share
- Net income $40.8M vs $37.4M net loss YoY
- Research and development expense $21.9M vs $27.4M YoY
- Cash and equivalents $220.5M; debt included $200.0M convertible notes and $385.0M revolver borrowings
- STARS-2 apraglutide site initiations expected in Q2 2026; confirmatory Phase III required by FDA
Risk Factors
- No risk-factors section provided; submitted text contains only insider trading arrangements and exhibits
- Director Julie McHugh adopted a Rule 10b5-1 sale arrangement expiring May 27, 2027, covering 21,571 securities
- Chief Accounting Officer Ronald Silver terminated and replaced a Rule 10b5-1 sale arrangement on March 17, 2026
- Silver’s new arrangement covers up to 253,000 Class A shares plus indeterminable Employee Stock Purchase Plan shares
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IRONWOOD PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.